Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 15,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $7.32, for a total transaction of $109,800.00. Following the transaction, the chief financial officer now directly owns 1,292,218 shares of the company’s stock, valued at $9,459,035.76. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Michael Secora also recently made the following trade(s):

• On Thursday, June 13th, Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $9.32, for a total transaction of $139,800.00.
• On Wednesday, April 17th, Michael Secora sold 23,124 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.58, for a total transaction of $175,279.92.

Recursion Pharmaceuticals Price Performance

NASDAQ RXRX traded up $0.45 on Thursday, hitting $7.68. The company had a trading volume of 8,418,305 shares, compared to its average volume of 6,204,676. The company has a market capitalization of $1.83 billion, a PE ratio of -4.86 and a beta of 0.83. The company’s fifty day moving average price is $8.74 and its 200-day moving average price is $9.81. Recursion Pharmaceuticals, Inc. has a 12-month low of $4.97 and a 12-month high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The company had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $11.10 million. During the same quarter in the previous year, the company posted ($0.34) EPS. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. On average, sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th. KeyCorp cut their price target on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a report on Thursday.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Benjamin F. Edwards & Company Inc. acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $26,000. National Bank of Canada FI boosted its position in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after acquiring an additional 1,500 shares during the last quarter. First Horizon Advisors Inc. acquired a new position in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $47,000. GAMMA Investing LLC boosted its position in shares of Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock valued at $48,000 after acquiring an additional 6,036 shares during the last quarter. Finally, Oxford Wealth Group LLC acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $106,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.